Trial Profile
A Phase II Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary)
- Indications Thymoma
- Focus Therapeutic Use
- 14 Mar 2022 Status changed from suspended to completed.
- 20 Apr 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
- 06 Oct 2020 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.